Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PR1 Peptide Vaccine in MDS
NCT00893997Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2006
- Primary completion
- Mar 2009
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PR1 leukemia peptide vaccine in myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Patient Immunologic Response at 29 weeks and Number of Patients With Clinical Response at 29 weeks. Started Jul 2006; status: terminated.
02
Drugs
PR1 leukemia peptide vaccine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00893997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00893997.